Table 3.
Longitudinal Lipid Analysis of Old OvH Female Monkeys on a Obesogenic Diet and Treated With Placebo, or ImE, or Estradiol 2 Years After OvH (DE)
| Total Cholesterol (mmol/L) ± SEM | Triglycerides (mmol/L) ± SEM | Very Low–Density Lipoprotein Cholesterol (mmol/L) ± SEM | Low-Density Lipoprotein Cheolesterol (mmol/L) ± SEM | HDL-C (mmol/L) ± SEM | Non-HDL-C (mmol/L) ± SEM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Placebo + DE | ImE | Placebo + DE | ImE | Placebo + DE | ImE | Placebo + DE | ImE | Placebo + DE | ImE | Placebo + DE | ImE |
| n | 12 | 7 | 12 | 7 | 12 | 7 | 12 | 7 | 12 | 7 | 12 | 7 |
| Month | ||||||||||||
| 0 | 3.69 ± 0.26 | 4.11 ± 0.39 | 0.48 ± 0.98 | 0.58 ± 0.07 | 0.24 ± 0.04 | 0.29 ± 0.04 | 2.26 ± 0.21 | 2.54 ± 0.29 | 1.18 ± 0.08 | 1.43 ± 0.31 | 2.48 ± 0.22 | 2.74 ± 0.27 |
| 6 | 6.35 ± 0.44 | 6.34 ± 0.58 | 0.76 ± 0.08 | 0.51 ± 0.06 | 0.38 ± 0.04 | 0.26 ± 0.03 | 3.05 ± 0.23 | 3.45 ± 0.32 | 2.95 ± 0.23 | 2.69 ± 0.27 | 3.97 ± 0.24 | 3.61 ± 0.33 |
| 12 | 6.03 ± 0.56 | 5.46 ± 0.52 | 0.69 ± 0.11 | 0.64 ± 0.15 | 0.35 ± 0.05 | 0.33 ± 0.07 | 2.93 ± 0.42 | 2.84 ± 0.29 | 2.78 ± 0.18 | 2.42 ± 0.30 | 3.24 ± 0.43 | 2.92 ± 0.26 |
| 18 | 6.28 ± 0.57 | 5.58 ± 0.27 | 0.85 ± 0.10 | 0.95 ± 0.31 | 0.43 ± 0.05 | 0.48 ± 0.15 | 3.01 ± 0.38 | 3.07 ± 0.33 | 2.87 ± 0.24 | 2.06 ± 0.29 | 3.41 ± 0.37 | 3.38 ± 0.32 |
| 24 | 6.33 ± 0.51 | 5.27 ± 0.38 | 0.77 ± 0.12 | 0.92 ± 0.19 | 0.39 ± 0.06 | 0.46 ± 0.14 | 3.34 ± 0.32 | 2.76 ± 0.27 | 2.63 ± 0.21 | 2.15 ± 0.30 | 3.69 ± 0.34 | 3.46 ± 0.36 |
| % Δ | 177 ± 15% | 130 ± 11%* | 195 ± 36% | 182 ± 60% | 196 ± 36% | 182 ± 60% | 155 ± 16% | 111 ± 6%† | 237 ± 18% | 176 ± 32% | 156 ± 15% | 131 ± 16% |
| 2-way ANOVA | ||||||||||||
| Interaction | P = 0.522 | P = 0.614 | P = 0.608 | P = 0.647 | P = 0.296 | P = 0.891 | ||||||
| Time | P = 0.0001 | P = 0.058 | P = 0.059 | P = 0.142 | P < 0.0001 | P = 0.044 | ||||||
| Treatment | P = 0.311 | P = 0.934 | P = 0.918 | P = 0.947 | P = 0.033 | P = 0.932 | ||||||
| Placebo | DE | ImE | Placebo | DE | ImE | Placebo | DE | ImE | Placebo | DE | ImE | Placebo | DE | ImE | Placebo | DE | ImE | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | 5 | 6 | 7 | 5 | 6 | 7 | 5 | 6 | 7 | 5 | 6 | 7 | 5 | 6 | 7 | 5 | 6 | 7 |
| Month | ||||||||||||||||||
| 30 | 6.10 ± 1.01 | 4.83 ± 0.46 | 4.98 ± 0.26 | 0.82 ± 0.27 | 1.04 ± 0.15 | 0.99 ± 0.19 | 0.42 ± 0.14 | 0.54 ± 0.07 | 0.50 ± 0.10 | 2.99 ± 0.57 | 2.31 ± 0.29 | 2.72 ± 0.58 | 2.72 ± 0.58 | 2.09 ± 0.24 | 1.76 ± 0.27 | 3.37 ± 0.63 | 2.79 ± 0.24 | 3.46 ± 0.42 |
| One-way ANOVA | P = 0.14 (K-W) | P = 0.56 (K-W) | P = 0.71 | P = 0.42 | P = 0.21 | P = 0.42 | ||||||||||||
Placebo + DE indicates data from the combined placebo and DE groups that had empty Silastic implants for 24 months of the study, before the DE group was placed on E treatment for the last 6 months of the study.
Abbreviations: % Δ, Percentage change from baseline (time 0) to month 24; K-W, Kruskal-Wallis nonparametric ANOVA.